BioSpace News Archive

Canopy Growth Corporation is pleased to announce that the Company’s shareholders voted overwhelmingly in favour of the resolution approving the issuance of common shares of Canopy Growth and certain amendments to certain outstanding Company warrants in connection with the Company’s previously announced proposed acquisition of Acreage Holdings, Inc..

Akero Therapeutics, Inc. announced the pricing of its initial public offering of 5,750,000 shares of common stock at a public offering price of $16.00 per share.

Zymeworks Inc. announced the pricing of its previously-announced underwritten public offering of 5,555,556 common shares and, to a certain investor, pre-funded warrants to purchase up to 4,166,690 common shares.

The half-million dollars in Alzheimer’s disease research grants recently announced by the Infectious Diseases Society of America Foundation, and the possibly millions of dollars of “high priority” grants now offered by the National Institute on Aging to study infectious agents in AD, are a “welcome affirmation” of the need to investigate more thoroughly the possible roles of germs in triggering AD, says Leslie Norins, MD, PhD, CEO of Alzheimer’s Germ Quest, Inc.

Shimmer Research, a global leader in wearable technology for research applications, and ClearSky Medical Diagnostics, a leader in analyzing wearable data for medical applications, today announced they are partnering to bring a new level of analytic capabilities to the use of wearable sensors in clinical research

Johnson & Johnson Medical Devices Companies* today announced that Ethicon** has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its VISTASEAL open and laparoscopic Dual Applicators (35 cm and 45 cm), three next generation airless spray devices that combine biologics with device technology to address mild to moderate surgical bleeding.

Myriad Genetic Laboratories, Inc., a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced the Japanese Ministry of Health, Labour, and Welfare has granted a second manufacturing and marketing approval for Myriad’s BRACAnalysis® Diagnostic System (i.e., “BRACAnalysis”) as a companion diagnostic with the PARP inhibitor, Lynparza® (olaparib)

Masters Speciality Pharma (“Masters”), a UK-headquartered pharmaceutical company specialising in the global distribution of high-quality, life-changing medicines, today announces it has been appointed to be the exclusive UK distributor of Siklos®, for the treatment of Sickle Cell Disease (SCD).

Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology currently focused on sexual health and pain, is pleased to announce the completion of patient recruitment for the first European Phase 3 study, “FM57”, of MED2005.

This World Sickle Cell Day, Medunik USA, a company dedicated to improving the health and quality of life of Americans with rare diseases, highlights the importance of early treatment of sickle cell disease.